FDA 483 - Sandoz GmbH

An FDA inspection of Sandoz GmbH in Schaftennau, a drug substance and drug product manufacturer, identified several significant deficiencies. Observations included inadequate support for microbial hold times, insufficient controls for testing machines, and deficiencies in standard operating procedures. The firm also lacked proper material control and release procedures for materials used in aseptic processing.